2.40
-0.03(-1.23%)
Currency In USD
| Previous Close | 2.43 |
| Open | 2.43 |
| Day High | 2.45 |
| Day Low | 2.37 |
| 52-Week High | 12.36 |
| 52-Week Low | 2.16 |
| Volume | 23,358 |
| Average Volume | 159,290 |
| Market Cap | 11.83M |
| PE | -0.25 |
| EPS | -9.73 |
| Moving Average 50 Days | 2.82 |
| Moving Average 200 Days | 6.89 |
| Change | -0.03 |
If you invested $1000 in Tempest Therapeutics, Inc. (TPST) 10 years ago, it would be worth $1.56 as of February 21, 2026 at a share price of $2.4. Whereas If you bought $1000 worth of Tempest Therapeutics, Inc. (TPST) shares 5 years ago, it would be worth $65.84 as of February 21, 2026 at a share price of $2.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
GlobeNewswire Inc.
Feb 11, 2026 11:59 AM GMT
Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assetsDevelopment approach prioritizes partner-funded and externally supported programs to generate clinical data
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
GlobeNewswire Inc.
Feb 04, 2026 9:47 PM GMT
All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in China planned for 2027Operational runway extended to m
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
GlobeNewswire Inc.
Jan 20, 2026 10:20 PM GMT
BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the reco